^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

SSTR5 expression

i
Other names: SSTR5, Somatostatin Receptor 5, Somatostatin Receptor Type 5, SS-5-R, Somatostatin Receptor Subtype 5, SSTR5, SS5-R, SS5R
Entrez ID:
24d
Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly. (PubMed, J Neurooncol)
PD-L1 expression and CD8 + T cell infiltration, either independently or combined with SSTR2 expression and T2WI-MRI intensity, could form a predictive model guiding clinical decisions on fg-SRL employment. Furthermore, targeting PD-L1 through immunotherapy and embracing second-generations of SRL with higher affinity to SSTR5 represent promising strategies to tackle fg-SRL resistance in somatotropinomas.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5)
|
PD-L1 expression • SSTR2 expression • SSTR5 expression
8ms
Medical Therapies in Functioning Pituitary Neuroendocrine Tumors(PitNETs) (PubMed, No Shinkei Geka)
In contrast, densely granulated somatotroph and corticotroph tumors express high levels of somatostatin receptors and are more responsive to somatostatin analogs. Since ACTH-producing PitNETs express SSTR5 without SSTR2, the second-generation somatostatin analog, pasireotide, is effective against ACTH-producing PitNETs.
Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5)
|
SSTR5 expression
8ms
Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials (ESMO 2023)
Comparative analysis of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 expression between the SySa cases (n=56) and the entire MASTER cohort (n=3,023) revealed significant differences for SSTR2, SSTR4, and SSTR5, with top 10% expression in 13, 31, and 22 patients, respectively. Conclusions Our study demonstrates the utility of broad molecular profiling in patients with advanced SySa for identifying subgroups of patients, whose molecular profiles may inform the design of future clinical trials.
Clinical • Metastases
|
TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex) • TAF1L (TATA-Box Binding Protein Associated Factor 1 Like)
|
SSTR5 expression • SS18-SSX fusion
1year
Immunohistochemical somatostatin receptor expression in insulinomas. (PubMed, APMIS)
Most insulinomas express SSTR2, which may be utilized in diagnostic imaging, and in planning individualized treatment strategies for insulinoma patients. Further studies are needed to clarify the association between SSTR profile and overall survival.
Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5)
|
SSTR2 expression • SSTR5 expression • SSTR Expression
1year
LncRNA SSTR5-AS1 as a Prognostic Marker Promotes Cell Proliferation and Epithelial-to-Mesenchymal Transition in Prostate Cancer. (PubMed, Crit Rev Eukaryot Gene Expr)
SSTR5-AS1 overexpression obtained opposite results on these protein markers in DU145 cells. In conclusion, these findings indicated that SSTR5-AS1 promotes PCa cell behaviors, which might provide a potential therapeutic target for PCa patients.
Journal
|
CDH1 (Cadherin 1) • SSTR (Somatostatin Receptor) • VIM (Vimentin) • CDH2 (Cadherin 2) • PCNA (Proliferating cell nuclear antigen) • SSTR5 (Somatostatin Receptor 5) • SSTR5-AS1 (SSTR5 Antisense RNA 1)
|
CDH1 expression • SSTR5 expression • VIM expression
1year
lncRNA SSTR5-AS1 Predicts Poor Prognosis and Contributes to the Progression of Esophageal Cancer. (PubMed, Dis Markers)
CCK-8 experiments indicated that silence of SSTR5-AS1 distinctly inhibited the proliferation of ESCA cells. Overall, ESCA patients with elevated SSTR5-AS1 had a worse chance of survival, suggesting it could be used as a prognostic and diagnostic biomarker for ESCA.
Journal
|
SSTR5 (Somatostatin Receptor 5) • SSTR5-AS1 (SSTR5 Antisense RNA 1)
|
SSTR5 expression
1year
GENETICALLY ENGINEERED HUMAN PITUITARY CORTICOTROPH TUMOR ORGANOIDS EXHIBIT DIVERGENT RESPONSES TO GLUCOCORTICOID RECEPTOR MODULATORS. (PubMed, Transl Res)
Relacorilant sensitized PitNET organoid responsiveness to Pasireotide. Therefore, our study identified the potential therapeutic use of relacorilant in combination with somatostatin analogs and demonstrated the advantages of relacorilant over Mifepristone, supporting its further development for use in the treatment of CD patients.
Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5)
|
SSTR2 expression • SSTR5 expression
|
relacorilant (CORT125134) • Korlym (mifepristone) • Mifeprex (mifepristone)
over1year
Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin. (PubMed, Int J Mol Sci)
Remarkably, CORT-silencing drastically enhanced proliferation rate and blunted the antitumor activity of SST-analogues (octreotide/pasireotide) in AI-PCa cells. Altogether, we provide evidence that SST/CORT system and SST-analogues could represent a potential therapeutic option for PCa, especially for CRPC, and that endogenous CORT could act as an autocrine/paracrine regulator of PCa progression.
Journal
|
SSTR2 (Somatostatin Receptor 2) • EGF (Epidermal growth factor) • MMP9 (Matrix metallopeptidase 9) • SSTR5 (Somatostatin Receptor 5)
|
SSTR2 expression • SSTR5 expression
over1year
Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with metastatic ACTH-secreting neuroendocrine neoplasm: A case report and literature review. (PubMed, Front Endocrinol (Lausanne))
This case had an aggressive clinical course, despite cytoreductive surgical treatment and somatostatin analog therapy. PET/CT imaging with two tracers is a molecular tool that demonstrates a biologic heterogeneity between a primary tumor and metastases and yields additional information that may influence the choice of the patient management strategy.
Clinical • Retrospective data • Review • Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5)
|
SSTR5 expression
over1year
Role of somatostatin receptor SSRT5-AS1 in predicting biomarkers of primary androgen deprivation therapy on prostate cancer in Indonesian population. (PubMed, Med J Malaysia)
This study demonstrated that high expression of SSRT5-AS1 is a promising biomarker to predict response to ADT in patients with prostate cancer.
Journal
|
SSTR (Somatostatin Receptor) • SSTR5 (Somatostatin Receptor 5) • SSTR5-AS1 (SSTR5 Antisense RNA 1)
|
SSTR5 expression
over1year
Corticotroph Macroadenomas with Extensions to Third Ventricle: Four Case Reports (ENDO 2022)
The findings from these case reports suggest that phenotypes of Cushing's disease (CD) and subclinical Cushing's disease (SCD) are associated with the differences between sparsely granulated corticotroph adenoma (SGCA) and densely granulated corticotroph adenoma (DGCA). Moreover, it is also suggested that ubiquitin-specific protease 8 (USP8) mutations correlate with somatostatin receptor type 5 (SSTR5) expression in macroadenomas that extend to the TV.
Clinical
|
SSTR (Somatostatin Receptor) • SSTR5 (Somatostatin Receptor 5)
|
SSTR5 expression
almost2years
P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs. (PubMed, Cancers (Basel))
In situ Proximity Ligation Assay and immunoflurescence experiments revealed that P720R USP8 mutant is still able to bind 14-3-3 proteins in AtT-20 cells, without affecting SSTR5 localization. In conclusion, P720R USP8 mutation might be considered as a molecular predictor of favourable response to pasireotide in corticotroph tumor cells.
Journal
|
SSTR5 (Somatostatin Receptor 5)
|
SSTR5 expression
almost2years
The Combined Effect of Downregulated RB1 and Overexpressed lncRNA SSTRS-AS1 on Prediction Time to Castration-Resistant Prostate Cancer: Indonesian Cohort Studies. (PubMed, Turk J Urol)
The combination of downregulation of RB1 and overexpression of SSTR5-AS1 is a strong predictor of shorter time to castration-resistant prostate cancer in the Indonesian population. Additionally, patients with International Society of Urological Pathology (ISUP) score >4 did not demonstrate this predictive value on time to castration-resistant prostate cancer.
Journal
|
RB1 (RB Transcriptional Corepressor 1) • SSTR5 (Somatostatin Receptor 5) • SSTR5-AS1 (SSTR5 Antisense RNA 1)
|
RB1 expression • RB1 overexpression • SSTR5 expression
2years
Clinicopathological characteristics and treatment options of the new grade 3 neuroendocrine tumor subgroup (NETs G3) (ENETS 2022)
Higher SSTR-5 expression, lower ki67 index and GEP origins of NETs G3 may have an impact on OS and also taking into account PFS during SA-monotherapy, it can be a stand-alone treatment option for this subgroup.
Clinical
|
SSTR (Somatostatin Receptor) • SSTR5 (Somatostatin Receptor 5)
|
SSTR positive • SSTR5 expression • SSTR Expression
2years
Correlation of Somatostatin Receptor 1-5 Expression, [Ga]Ga-DOTANOC, [F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms. (PubMed, Cancers (Basel))
SSTR2 was the only SSTR subtype to correlate with [Ga]Ga-DOTANOC PET/CT. Our prospective study confirms SSTR2 to be of the highest impact for SST PET/CT signal.
Clinical • Clinical data • Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5)
|
SSTR2 expression • SSTR5 expression
over2years
Somatostatin Receptors in Human Meningiomas-Clinicopathological Aspects. (PubMed, Cancers (Basel))
SSTRs, and especially SSTR2, are useful in the diagnostics of meningiomas, even though their prognostic value appears limited. Digital scoring is valuable to ensure reproducibility.
Clinical • Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5)
|
SSTR5 expression
over2years
The prognostic role of the immunohistochemical markers H3K27me3, SSTR1-5 and BAP1 in meningioma (SNO 2021)
The loss of BAP1 expression in meningioma cells was a negative prognostic factor with a shorter progression-free survival. Taken together, we present potential candidate prognostic markers that could be further investigated in prospective cohorts to determine their clinical utility.
BAP1 (BRCA1 Associated Protein 1) • SSTR (Somatostatin Receptor) • SSTR5 (Somatostatin Receptor 5)
|
SSTR5 expression
over2years
Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy? (PubMed, Hormones (Athens))
The present study indicates that there is no significant relationship between the expression rates of receptor subtypes and the parameters we analyzed. However, our study revealed that smaller adenomas have a lower baseline GH level (p = 0.015), IHC with monoclonal antibodies appears to be a suitable method to determine the expression rates of SSTR2a and 5 at protein levels, as it is not possible to draw conclusions regarding receptor subtypes solely on the basis of the parameters analyzed.
Clinical • Journal
|
SSTR (Somatostatin Receptor) • IGF1 (Insulin-like growth factor 1) • SSTR5 (Somatostatin Receptor 5)
|
SSTR5 expression • SSTR Expression
over2years
Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST ) in pituitary and pancreatic neuroendocrine tumors. (PubMed, Mol Oncol)
In PanNETs cell lines, SSTR5-AS1 silencing downregulated SSTR5 expression, altered aggressiveness features, and influenced pasireotide response. These results provide evidence that SSTR5 expression in PitNETs and PanNETs can be epigenetically regulated by the SSTR5-AS1 antisense transcript and, indirectly, by DNA methylation, which may thereby impact tumor behavior and treatment response.
Journal
|
SSTR (Somatostatin Receptor) • SSTR5 (Somatostatin Receptor 5)
|
SSTR5 expression
over2years
The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. (PubMed, Exp Ther Med)
The results demonstrated the decrease in SSTR2 expression with increasing malignancy and tumor stage. The SSTR2-positive expression in neuroendocrine carcinomas and adenocarcinoma ex-goblet cell carcinoid provides evidence for the benefits of somatostatin analog treatment associated with surgery and chemotherapy.
Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5) • SYP (Synaptophysin) • CHGA (Chromogranin A)
|
SSTR2 expression • SSTR5 expression • SSTR Expression • SSTR2 positive
almost3years
mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs. (PubMed, Endocr Relat Cancer)
Notably, SSTRs expression was heterogeneous within the same lesions in most of the lesions. Overall, despite primary and metastatic ileal NETs show a similar molecular landscape, tumor grading and mTOR signaling pathway may diverge in the metastatic setting, thus affecting prognosis and treatment.
Journal
|
PTEN (Phosphatase and tensin homolog) • SSTR (Somatostatin Receptor) • MIR21 (MicroRNA 21) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • SSTR5 (Somatostatin Receptor 5)
|
PTEN expression • SSTR5 expression